{"id":62412,"date":"2026-04-04T23:02:57","date_gmt":"2026-04-04T15:02:57","guid":{"rendered":"https:\/\/flcube.com\/?p=62412"},"modified":"2026-04-04T23:02:59","modified_gmt":"2026-04-04T15:02:59","slug":"youcare-pharmas-ykyy018-inhalation-therapy-expands-to-covid-19-clinical-study-following-rsv-development-success-2","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62412","title":{"rendered":"Youcare Pharma&#8217;s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success"},"content":{"rendered":"\n<p><strong>Beijing Sun-Novo Pharmaceutical Research Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688621:SHA\">SHA: 688621<\/a>) announced it has received approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to initiate a <strong>clinical study<\/strong> for its investigational <strong>small interfering nucleotide drug ABA001<\/strong> for the treatment of <strong>hypertension<\/strong>, marking a significant advancement in RNA interference-based cardiovascular therapeutics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-development-status\">Regulatory Milestone &amp; Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Beijing Sun-Novo Pharmaceutical Research Co., Ltd.<\/td><\/tr><tr><td><strong>Stock Code<\/strong><\/td><td>SHA: 688621<\/td><\/tr><tr><td><strong>Investigational Drug<\/strong><\/td><td>ABA001<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Small interfering nucleotide (siRNA) conjugated with GalNAc delivery system<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>Hypertension<\/td><\/tr><tr><td><strong>Regulatory Approval<\/strong><\/td><td>NMPA clinical study approval (China)<\/td><\/tr><tr><td><strong>Mechanism Target<\/strong><\/td><td>Angiotensinogen (AGT) messenger RNA (mRNA)<\/td><\/tr><tr><td><strong>Delivery System<\/strong><\/td><td>N-acetylgalactosamine (GalNAc) conjugation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-therapeutic-innovation\">Mechanism of Action &amp; Therapeutic Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Targeting:<\/strong> GalNAc conjugation enables <strong>liver-specific delivery<\/strong>, directing the siRNA payload exclusively to hepatocytes where angiotensinogen is primarily synthesized<\/li>\n\n\n\n<li><strong>Source-Level Intervention:<\/strong> Utilizes <strong>siRNA interference mechanism<\/strong> to silence AGT mRNA at the transcriptional level, preventing protein synthesis rather than blocking downstream receptors<\/li>\n\n\n\n<li><strong>RAAS System Inhibition:<\/strong> Fundamentally disrupts the <strong>renin-angiotensin-aldosterone system (RAAS)<\/strong> at its origin by blocking AGT production, the precursor to all downstream angiotensin peptides<\/li>\n\n\n\n<li><strong>Sustained Effect Profile:<\/strong> Based on clinical precedent with similar siRNA agents, ABA001 is expected to provide <strong>extended therapeutic duration<\/strong> with infrequent dosing requirements<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-validation-amp-competitive-landscape\">Scientific Validation &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Reference Compound<\/th><th>Development Stage<\/th><th>Key Clinical Findings<\/th><th>Relevance to ABA001<\/th><\/tr><\/thead><tbody><tr><td><strong>Zilebesiran<\/strong><\/td><td>Phase 2 completed<\/td><td>Single dose provides sustained BP reduction for up to 24 weeks<\/td><td>Validates siRNA mechanism targeting AGT for hypertension<\/td><\/tr><tr><td><strong>ABA001<\/strong><\/td><td>Phase 1 initiation<\/td><td>Preclinical data demonstrates target engagement and BP lowering<\/td><td>First Chinese-developed siRNA for hypertension<\/td><\/tr><tr><td><strong>Current Standard of Care<\/strong><\/td><td>Market established<\/td><td>Daily oral medications requiring strict adherence<\/td><td>ABA001 offers potential for quarterly or biannual dosing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The strong clinical validation from zilebesiran studies provides a robust scientific foundation for ABA001 development, de-risking the mechanism while positioning Sun-Novo as a pioneer in China&#8217;s RNA therapeutics landscape.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-implications\">Market Opportunity &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hypertension Burden:<\/strong> Affects over 270 million adults in China alone, representing one of the largest addressable markets in cardiovascular disease<\/li>\n\n\n\n<li><strong>Adherence Challenge:<\/strong> Current daily medication regimens suffer from poor long-term adherence rates (estimated &lt;50%), creating significant unmet need for long-acting alternatives<\/li>\n\n\n\n<li><strong>Innovation Premium:<\/strong> First-in-class siRNA approach in China&#8217;s hypertension market could command premium pricing and rapid adoption among specialists<\/li>\n\n\n\n<li><strong>Platform Potential:<\/strong> Success with ABA001 would validate Sun-Novo&#8217;s siRNA platform for expansion into other cardiovascular and metabolic indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-strategy-amp-investment-thesis\">Development Strategy &amp; Investment Thesis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>De-Risked Approach:<\/strong> Leveraging proven siRNA mechanism with established safety profile reduces clinical development risk<\/li>\n\n\n\n<li><strong>Manufacturing Expertise:<\/strong> GalNAc-conjugated siRNA production requires specialized capabilities that create competitive barriers to entry<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> Potential for international partnerships and regulatory filings following successful Chinese clinical development<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> Expands Sun-Novo&#8217;s pipeline beyond traditional small molecules into next-generation genetic medicines<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Sun-Novo&#8217;s clinical development plans, regulatory approvals, and commercial expectations for ABA001. Actual results may differ materially due to risks including clinical trial outcomes, regulatory decisions, manufacturing challenges, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688621_20260403_9KQ2.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688621_20260403_9KQ2.\"><\/object><a id=\"wp-block-file--media-57936d64-1271-4f56-8ac4-32181b3a3894\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688621_20260403_9KQ2.pdf\">688621_20260403_9KQ2<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688621_20260403_9KQ2.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-57936d64-1271-4f56-8ac4-32181b3a3894\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1262,2604],"class_list":["post-62412","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-sha-688621","tag-sun-novo-pharmaceutical-research"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Youcare Pharma&#039;s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate a clinical study for its investigational small interfering nucleotide drug ABA001 for the treatment of hypertension, marking a significant advancement in RNA interference-based cardiovascular therapeutics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62412\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Youcare Pharma&#039;s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success\" \/>\n<meta property=\"og:description\" content=\"Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate a clinical study for its investigational small interfering nucleotide drug ABA001 for the treatment of hypertension, marking a significant advancement in RNA interference-based cardiovascular therapeutics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62412\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-04T15:02:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-04T15:02:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62412#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62412\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Youcare Pharma&#8217;s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success\",\"datePublished\":\"2026-04-04T15:02:57+00:00\",\"dateModified\":\"2026-04-04T15:02:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62412\"},\"wordCount\":498,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"SHA: 688621\",\"Sun-Novo Pharmaceutical Research\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62412#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62412\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62412\",\"name\":\"Youcare Pharma's YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-04T15:02:57+00:00\",\"dateModified\":\"2026-04-04T15:02:59+00:00\",\"description\":\"Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a clinical study for its investigational small interfering nucleotide drug ABA001 for the treatment of hypertension, marking a significant advancement in RNA interference-based cardiovascular therapeutics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62412#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62412\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62412#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Youcare Pharma&#8217;s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Youcare Pharma's YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a clinical study for its investigational small interfering nucleotide drug ABA001 for the treatment of hypertension, marking a significant advancement in RNA interference-based cardiovascular therapeutics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62412","og_locale":"en_US","og_type":"article","og_title":"Youcare Pharma's YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success","og_description":"Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a clinical study for its investigational small interfering nucleotide drug ABA001 for the treatment of hypertension, marking a significant advancement in RNA interference-based cardiovascular therapeutics.","og_url":"https:\/\/flcube.com\/?p=62412","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-04T15:02:57+00:00","article_modified_time":"2026-04-04T15:02:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62412#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62412"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Youcare Pharma&#8217;s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success","datePublished":"2026-04-04T15:02:57+00:00","dateModified":"2026-04-04T15:02:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62412"},"wordCount":498,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["SHA: 688621","Sun-Novo Pharmaceutical Research"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62412#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62412","url":"https:\/\/flcube.com\/?p=62412","name":"Youcare Pharma's YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-04T15:02:57+00:00","dateModified":"2026-04-04T15:02:59+00:00","description":"Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a clinical study for its investigational small interfering nucleotide drug ABA001 for the treatment of hypertension, marking a significant advancement in RNA interference-based cardiovascular therapeutics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62412#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62412"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62412#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Youcare Pharma&#8217;s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62412"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62412\/revisions"}],"predecessor-version":[{"id":62415,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62412\/revisions\/62415"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}